Is interleukin-10 gene polymorphism a predictive marker in HCV infection?

Cytokine and Growth Factor Reviews

Volumn 23, Issue 1-2, 2012, Pages 47-59

  Światek, Bogna J ^a  

^a INSTITUTE OF HUMAN GENETICS   (Poland)

Author keywords

Clinical outcome of hepatitis C; Hepatitis C virus; Interleukin 10; Response to hepatitis C therapy; Single nucleotide polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; INTERLEUKIN 10; MESSENGER RNA; RECOMBINANT INTERLEUKIN 10; RIBAVIRIN;

COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; GENE; GENETIC MARKER; GENETIC POLYMORPHISM; HAPLOTYPE; HEPATITIS C; HUMAN; IL 10 GENE; INFECTION SENSITIVITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKIN-10; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; PROGNOSIS; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84858332809     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.01.005     Document Type: Review

References (136)

1. Baldo V., Baldovin T., Trivello R., Floreani A. Epidemiology of HCV infection. Curr Pharm Des 2008, 14:1646-1654.
2. Hwang S.J. Hepatitis C virus infection: an overview. J Microbiol Immunol Infect 2001, 34:227-234.
3. Barrett S., Goh J., Coughlan B., Ryan E., Stewart S., Cockram A., et al. The natural course of hepatitis C virus infection after 22 years in a unique homogeneous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001, 49:423-430.
4. Boyer N., Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000, 32:98-112.
5. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
6. Kioyosawa K., Soneyama T., Tanaka E., Gibo Y., Yoshuzawa K., Nakano Y., et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990, 12:671-675.
7. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999, 31(Suppl. 1):9-16.
8. Pawlotsky J., Roudot-Thoraval F., Simmonds P., Mellor J., Ben Yahia M.B., Andre C., et al. Extrahepatic immunologic manifestation in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995, 122:169-173.
9. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997, 349:825-832.
10. Seeff L.B. The natural history of chronic hepatitis C virus infection. Clin Liver Dis 1997, 1:587-602.
11. Tong M.J., el-Farra N.S., Reikes A.R., Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995, 332(22):1463-1466.
12. Lau J.Y., Tam R.C., Liang T.J., Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002, 35:1002-1009.
13. McHutchinson J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis International Therapy Group. N Engl J Med 1998, 339:1485-1492.
14. Thomas D.J., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 2000, 284:450-456.
15. Thio C.L., Thomas D.L., Carrington M. Chronic viral hepatitis and the human genome. Hepatology 2000, 31:819-827.
16. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001, 52:113-116.
17. Pawlotsky J.M. Hepatitis C virus interaction: virus/host interactions. J Viral Hepat 1998, 5(Suppl. 1):3-8.
18. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000, 20:127-214.
19. Prezzi C., Cascaiaro M.A., Francavilla V., Schiafella E., Finocchi L., Chircu L.V. Virus specific CD8(+) T cells with type 1 and type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 2001, 31:894-906.
20. Biron C.A. Cytokines in the generation of immune responses to, and resolution of virus infection. Curr Opin Immunol 1994, 6:530-538.
21. Del Prete G., Maggi E., Romagnani S. Human Th1 and Th2 cells: functional properties, mechanisms of regulation and the role in disease. Lab Invest 1994, 70:229-306.
22. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996, 17:138-146.
23. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996, 23:909-916.
24. Sher A., Coffman R.L. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol 1992, 10:385-409.
25. Koziel M.J. Cytokines in viral hepatitis. Semin Liver Dis 1994, 19:157-168.
26. Missale G., Ferrari C., Fiaccadori F. Cytokine mediators in acute inflammation and chronic course of viral hepatitis. Ann Ital Med Int 1995, 10:14-18.
27. Napoli J., Bishop G.A., McGuinness P.H., Painter Dm, McCaughan G.W. Progressive liver injury in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996, 24:6-9.
28. Ollier W.E. Cytokine genes and disease susceptibility. Cytokine 2004, 28:174-178.
29. Chen T.Y., Hsieh Y.S., Wu T.T., Yang S.F., Wu C.J., Tsay G.J., et al. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007, 150(2):116-121.
30. Kau A., Vermehren J., Sarrazin Ch. Treatment predictors of sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-651.
31. Mabee C.L., Criooin J.S., Lee W.M. Review article: interferon and hepatitis C - factors predicting therapeutic outcome. Aliment Pharmacol Ther 1998, 12:509-518.
32. Commins S., Strinke J.W., Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. Allergy Clin Immunol 2008, 121:1108-1111.
33. Fickenscher H., Hor S., Kupers H., Knappe A., Wittmann S., Sticht H. The interleukin-10 family of cytokines. Trends Immunol 2002, 23:89-95.
34. Pestka S., Krauze C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
35. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines inhuman inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008, 19:41-52.
36. Chomarat P., Rissoan M.C., Banchereau J., Miossec P. Interferon gamma inhibits interleukin 10 production by monocytes. J Exp Med 1993, 177:523-527.
37. Couper K.N., Blount D.G., Riley E.M. IL-10: the master regulator of immunity to infection. J Immunol 2008, 180:5771-5777.
38. Fillatreau S., Gray D., Anderton S.M. Not always bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008, 8:391-397.
39. Mehrotra P.T., Donnelly R.P., Wong S., Kanegane H., Geremew A., Mostowski H.S., et al. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol 1998, 160:2637-2644.
40. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
41. O'Garra A., Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 2007, 7:425-428.
42. Ryan J.J., Kashyap M., Bailey M., Kennedy S., Speiran K., Brenzovich J., et al. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol 2007, 27:25-32.
43. Williams L.M., Ricchetti G., Sarma U., Smallie T., Foxwell B.M. Interleukin-10 suppression of myeloid cell activation - a continuing puzzle. Immunology 2004, 1113:281-292.
44. Wolk K., Kunz S., Asadullah K., Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members?. J Immunol 2002, 168:5397-5402.
45. Wan S., LeClerc J.L., Schmartz D., Barvais L., Huynh C.H., Deviere J., et al. Hepatic release of interleukin-10 during cardiopulmonary bypass in steroid-pretreated patients. Am Heart J 1997, 133:335-339.
46. Sabat R., Gruetz G., Warszawska K., Kirsch S., Witte E., Wolk K., et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010, 21(5):331-344.
47. Akdis C.A., Blaser K. Mechanisms of interleukin-10 mediated immune suppression. Immunology 2001, 103:131-136.
48. De Vries J.E. Immunosuppressive and anti-inflammatory properties of interleukin-10. Ann Med 1995, 27:537-541.
49. Lauw F.N., Pajkrt D., Hack C.E., Kurimoto M., van Deventer S.J., van der P.T. Proinflammatory affects of IL-10 during endotoxemia. J Immunol 2000, 165:2783-2789.
50. Mege J.L., Meghari S., Honstettre A., Capo C., Raoult D. Two faces of interleukin 10 in human infectious diseases. Lancet Infect Dis 2006, 6:557-569.
51. Howell W.M., Rose-Zerilli M.J. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006, 5:143-149.
52. Helminem M.E., Kilpinnen S., Virta M., Hurme M. Susceptibility to primary Epstein-Bar virus infection is associated with interleukin-10 gene promoter polymorphism. J Infect Dis 2001, 184:777-780.
53. Shin H.D., Winkler C., Stephens J.C., Bream J., Young H., Goederr J.J., et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A 2000, 97(26):14467-14472.
54. Miyazoe S., Hamasaki K., Nakata K., Kajiya Y., Kitajima K., Nakao K., et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002, 97:2086-2092.
55. Eskdale J., Wordsworth P., Bowman S., Field M., Gallagher G. Associations between polymorphisms and IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997, 49:635-639.
56. De Jong B.A., Westendrop R.G.J., Eskdale J., Uitdehaag B.M.J., Huizinga T.J. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum Immunol 2002, 63:281-285.
57. Anaya J.M., Corrcea P.A., Herrera M., Eskdale J., Gallagher G. Interleukin 10 (IL-10) influences autoimmune response in primary Sjögeren's syndrome and is linked to IL-10 gene polymorphism. J Rheumatol 2002, 29:1874-1876.
58. Tagore A., Gonsalkorale W.M., Pravica V., Hajeer A.H., McMahon R., Whorwell P.J., et al. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 1999, 54:386-390.
59. Hajeer A.H., Lazarus M., Mageed R.A., Vencovsky J., Hutchinson I.V. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 1998, 27:142-145.
60. Asadullah K., Eskdale J., Wiese A., Gallagher G., Friederich M., Sterry W. Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol 2001, 116:975-978.
61. Howell W.M., Turner S.J., Bateman A.C., Theaker J.M. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2000, 2:25-31.
62. Alamartine E., Berthoux P., Mariat C., Cambazard F., Berthoux F. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 2003, 120:99-103.
63. Wu M.S., Wu C.Y., Chen C.J., Lin M.T., Shun C.T., Lin J.T. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003, 104:617-623.
64. Shin H.D., Park B.L., Kim L.H., Jung J.H., Kim J.Y., Yoon J.H., et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 2003, 12:901-906.
65. Eskdale J., Kube D., Tesch H., Gallagher G. Mapping the human IL-10 gene and further characterization of the 5' flanking sequence. Immunogenetics 1997, 46:120-128.
66. Kim J.M., Brannan C.I., Copeland N.G., Jenkins N.A., Khan T.A., Moore K.W. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol 1992, 148:3618-3623.
67. D'Alfonso S., Rampi M., Rolando V., Giordano V., Giordano M., Momigliano-Richiardi P. New polymorphisms in the IL-10 promoter region. Genes Immun 2000, 1:231-233.
68. Eskdale J., Kube D., Gallagher G. A second dinucleotide polymorphic repeat in the 5' flanking region of the human IL10 gene. Immunogenetics 1996, 45:82-83.
69. Gibson A.W., Edberg J.C., Wu J., Westendrop R.G., Huizinga T.W., Kimberly R.P. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001, 166:3915-3922.
70. Kube D., Rieth H., Eskdale J., Kremsner P.G., Gallagher G. Structural characterisation of the distal 5' flanking region of the human Interleukin-10 gene. Genes Immun 2001, 2:181-190.
71. Tountas N.A., Cominelli F. Identification and initial characterisation of two polymorphisms in the human interleukin-10 promoter. Eur Cytokine Netw 1996, 7:578.
72. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:18.
73. Eskdale J., Hallagher G., Verweij C.L., Keijsers V., Westerndrop R.G., Hutzinga T.W. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998, 95:9465-9470.
74. Koss K., Fanning G., Welsh K., Jewell D. Interleukin-10 gene promoter polymorphism in English and Polish healthy controls. Polymerase chain reaction haplotyping using 3' mismatches in forward and reverse primers. Genes Immun 2000, 1:321-324.
75. Donger C., Georges J.L., Nicaud V., Morrison C., Evans A., Kee F., et al. New polymorphisms in the interleukin-10 gene - relationships to myocardial infarction. Eur J Clin Invest 2001, 31:9-14.
76. Lazarus R., Klimecki W.T., Palmer L.J., Kwiatkowski D.J., Silverman E.K., Brown A., et al. Single nucleotide polymorphisms in the Interleukin-10 gene: differences in frequencies, linkage disequilibrium patterns and haplotypes in three United States ethnic groups. Genomics 2002, 80:223-228.
77. Eskdale J., Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 1995, 42:444-445.
78. Eskdale J., Keijsers V., Huizinga T., Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999, 1:151-155.
79. Reuss E., Fimmers R., Kruger A., Becker C., Rittner C., Hohler T. Differential regulation of interleukin-10 production by genetic and environmental factors - a twin study. Genes Immun 2002, 3:407-413.
80. Suárez A., Castro P., Alonso R., Mozo L., Gutiérrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003, 75:711-717.
81. Rees L.E., Wood N.A., Gillepsie K.M., Lai K.N., Gaston K., Mathleston P.W. The interleukin-10-1082G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 2002, 59:560-569.
82. Steinke J.W., Berekzi E., Hagman J., Boriah L. Functional analysis of -571 IL-10 promoter polymorphism reveals a suppressor element controlled by sp1. J Immunol 2004, 173:3215-3222.
83. Clerici M., Wynn T.A., Berzolsky J.A., Blatt S.P., Hendrix C.W., Sher A., et al. Role of interleukn-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994, 93:768-775.
84. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., ShorthouseC, Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
85. Constantini P.K., Wawrzynowicz-Syczewska M., Clare M., Boron-Kaczmarska A., McFarlane I.G., Cramp M.E., et al. Interleukin-1, interleukin-10 and tumor necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002, 22:404-412.
86. Haanpää M., Nurmikko T., Hurme M. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis 2002, 34:112-114.
87. Kurzawski M., Pawlik A., Czerny B., Domański L., Rożański J., Droździk M. Frequencies of the common promoter polymorphisms in cytokines genes in a Polish population. Int J Immunogenet 2005, 32:285-291.
88. Meenagh A., Williams F., Ross O.A., Patterson C., Gorodezky C., Hammond M., et al. Frequency of cytokine polymorphisms in populations from Western Europe, Africa, Asia, the Middle East and South America. Hum Immunol 2002, 63:1055-1061.
89. Opdal S.H., Opstad A., Vege A., Rognum T.O. IL-10 gene polymorphisms are associated with infectious cause of sudden infant death. Hum Immunol 2003, 64:1183-2118.
90. Chen T.Y., Hsich Y.S., Wu T.T., Yang S.F., Wu C.J., Tsay G.J., et al. Impact of serum levels and genetic polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007, 150:116-121.
91. Chuang J.Y., Yang S.S., Lu Y.T., Hsieh Y.Y., Chen C.Y., Chang S.C., et al. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009, 41:424-430.
92. Gao O.J., Liu D.W., Zhang S.Y., Jia M., Wang L.M., Wu L.H., et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 2009, 15:5610-5619.
93. Kusumoto K., Uto H., Hayashi K., Takahama Y., Nakao H., Suruki R., et al. Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 2006, 34:24-31.
94. Hoffmann S.C., Stanley E.M., Cox E.D., DiMerucio B.S., Koziol D.E., Harlan D.M., et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002, 2:560-567.
95. Aborsangaya K.B., Dembinski I., Khatkar S., Alphonse M.P., Nickerson P., Rempel J.D. Impact of aboriginal ethnicity on HCV core-inducted IL-10 synthesis: interaction with IL-10 gene polymorphisms. Hepatology 2007, 45:623-630.
96. Abayli B., Canataroĝlu A., Akkiz H. Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection. Turk J Gastroenterol 2003, 14:7-11.
97. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996, 24:6-9.
98. Jia H., Du J., Zhu S., Ma Y., Cai H. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre- and post antiviral treatment. Chin Med J 2003, 116:605-608.
99. Kakumu S., Okumura A., Isikawa T., Yano M., Enomoto A., Nishimura H., et al. Serum levels of IL-10, IL-15 and soluble tumor necrosis factor-alpha (TNF-α) receptors in type C chronic liver disease. Clin Exp Immunol 1997, 109:458-463.
100. Osna N., Silonova G., Vigert N., Hagina E., Kuse V., Giedraitis V., et al. Chronic hepatitis C; T-helper1/T-helper2 imbalance could cause virus persistence in peripheral blood. Scand J Clin Lab Invest 1997, 57:703-710.
101. Piazzolla G., Tortorella C., Schiraldi O., Antonaci S. Relationship between interferon-gamma, interleukin-10, and interleukin-12 production in chronic hepatitis C and in vitro effects of interferon-α. J Clin Immunol 2000, 20:54-61.
102. Verma V., Chakravarti A., Kar P. Cytokine levels of TGF-β, IL-10 and sTNFαRII in type C chronic liver disease. Dig Dis Sci 2008, 53:2233-2237.
103. Kakumu S., Okumura A., Ishikawa T., Iwata K., Yano M., Yoshioka K. Production of interleukins 10 and 12 by peripheral blond mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1997, 108:138-143.
104. Woitas R.P., Petersen U., Moshage D., Brackmann H.H., Matz B., Sauerbruch T., et al. HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World J Gastroeneterol 2002, 8:562-566.
105. Gramenzi A., Andreone P., Loggi E., Foschi F.G., Cursaro C., Margotti M., et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat 2005, 12:523-530.
106. Afzal M.S., Tahir S., Salman A., Baig T.A., Shafi T., Zaidi N.U., et al. Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries 2011, 5:473-479.
107. Lu Y.L., Wu X., Huang H.L., Dai L.C. Allele polymorphisms of interleukin-10 and hepatitis B, C virus infection. Chin Med J 2010, 123:1338-1344.
108. Vidigal P.G., Germer J.J., Zein N.N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002, 36:271-277.
109. Paladino N., Fainboim H., Theiler G., Schroder T., Munoz A.E., Flores A.C., et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol 2006, 80:9144-9150.
110. Pár A., Kisfali P., Melegh B., Tornai I., Gervain J., Szalay F., et al. Cytokine (IL-10, IL-28B and LT-A) gene polymorphisms in chronic hepatitis C virus infection. Clin Exp Med J 2011, 5(1):9-19.
111. Zhang L.Z., Zhang T.C., Pan F.M., Zhang Z.H., Li X. Interleukin-10 gene polymorphisms in association with susceptibility to chronic hepatitis C virus infection: a meta-analysis study. Arch Virol 2010, 155:1839-1842.
112. Bouzgarrou N., Hassen E., Farhat K., Bahri O., Gabbouj S., Mamouri N., et al. Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 2009, 70:230-236.
113. Dogra G., Chakravarti A., Kar P., Chawla Y.K. Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response. Hum Immunol 2011, 72(10):935-939.
114. Mangia A., Sanoto R., Piattelli M., Pazienza V., Grifa G., Iacobellis A., et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 2004, 25:103-109.
115. Zein N.N., Germer J.J., El-Zayadi A.R., Vidigal P.G. Ethnic differences in polymorphisms of tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in patients with chronic hepatitis C virus infection. Am J Trop Med Hyg 2004, 70:434-437.
116. Tsukamoto H. Is interleukin-10 antifibrogenic in chronic liver injury?. Hepatology 1998, 28:1708-1709.
117. Nelson D.R., Lauwers G.Y., Lau J.Y., Davis G.L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000, 118:655-660.
118. Abbas Z., Moatter T., Hussainy A., Jafri W. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005, 11(42):6656-6661.
119. Powell E.E., Edwards-Smith C.J., Hay J.L., Clouston A.D., Crawford D.H., Shorthouse C., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31:828-833.
120. Morgan T.R., Lambrecht R.W., Bonkovsky H.L., Chung R.T., Naishadham D., Sterling R.K., et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008, 49:548-556.
121. Ishida C., Ikebuchi Y., Okamoto K., Murawaki Y. Functional gene polymorphisms of interleukin-10 are associated with liver disease progression in Japanese patients with hepatitis C virus infection. Intern Med 2011, 50:659-666.
122. Knapp S., Hennig B.J.W., Frodsham A.J., Zhang L., Hellier S., Wright M., et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003, 55:362-369.
123. Ognajovic S., Yuan J.M., Chaptman A.K., Fan Y., Yu M.C. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk-non-Asians of USA. Carcinogenesis 2009, 30:758-762.
124. Yang Y., Luo C., Feng R., Bi S. The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta analysis. J Cancer Res Clin Oncol 2011, 137:947-952.
125. Lio D., Caruso C., Di Stefano R., Romano G.C., Ferraro D., Scola L. IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003, 64:674-680.
126. Oleksyk T.K., Thio C.L., Truelove A.L., Goedert J.J., Donfield S.M., Krik G.D. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005, 6:347-357.
127. Minton E.J., Smillie D., Smith P., Shipley S., McKendrick M.W., Gleeson D.C., et al. Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or -10 genes. Hum Immunol 2005, 66:127-132.
128. Shen X., Hong F., Nguyen V.A., Gao B. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 2000, 480:132-136.
129. Tam R.C., Pai B., Bard J., Lim C., Averett D.R., Phan U.T., et al. Ribavirin polarizes human T cell responses towards a Th1 cytokine profile. J Hepatol 1999, 30:376-382.
130. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., Naoumov N. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118:346-355.
131. Lasarte J.J., Gracia-Granero M., Lopez A., Casares N., Gracia N., Civeira M.P., et al. Cellular immunity to hepatic C virus core protein and the response to interferon patients with chronic hepatitis C. Hepatology 1998, 28:815-822.
132. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., Velde A., Figor C., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991, 174(915-924).
133. Kuzushita N., Hayashi N., Katayama K., Kanto T., Oshita M., Hagiwara H., et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis. Scand J Gastroenterol 1997, 32:169-174.
134. Torre F., Rossol S., Pelli N., Basso M., Delfino A., Picciotto A. Kinetics of soluble tumor necrosis factor (TNF)-α receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-α alone, IFN-α plus amantadine or plus ribavirin. Clin Exp Immunol 2004, 136:507-512.
135. Yee L.J., Tang J., Gibson A.W., Kimberly R., Van Leeuwen D.J., Kaslow R.A. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001, 33:708-712.
136. Lange Ch.M., Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011, 55(3):692-701.